Compare ATLX & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATLX | NKTX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.1M | 154.8M |
| IPO Year | 2012 | 2020 |
| Metric | ATLX | NKTX |
|---|---|---|
| Price | $4.43 | $2.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $11.33 |
| AVG Volume (30 Days) | 322.0K | ★ 585.8K |
| Earning Date | 05-08-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.08 | 11.88 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,491.00 | N/A |
| Revenue This Year | $64,564.67 | N/A |
| Revenue Next Year | $785.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.54 | $1.42 |
| 52 Week High | $8.25 | $2.81 |
| Indicator | ATLX | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 48.72 |
| Support Level | $4.32 | $1.95 |
| Resistance Level | $5.25 | $2.32 |
| Average True Range (ATR) | 0.31 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 36.82 | 58.58 |
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.